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Primary Nocturnal Enuresis (PNE), or nighttime bedwet-
ting, is the second most common chronic ailment in child-
hood. Fifteen to 20% of 5 year-olds wet at least monthly.
It has been estimated that up to 10% of children with
PNE will remain enuretic throughout their lifetime if
untreated.
OBJECTIVE: This model was developed to determine the
cost effectiveness of therapies for PNE.
METHODS: A decision tree model was developed on
software designed by Treeage Software Inc. to access 
the cost-effective treatment of PNE. The model assumed
6 months of initial treatment for 100 patients in each
group. If the initial treatment failed or the patient
relapsed, they were retreated with an alternative therapy.
Probabilities used in the model to determine patient
responses, relapses, and complication rates were obtained
from published clinical trials. The model includes direct
cost including drug acquisition, physician consultation,
intensive behavioral management (IBM), relapses, and
complications. Probabilities and direct cost data for vaso-
pressin (DDAVP), IBM, minor or serious adverse events
(AE), and relapses were included in the model. Indirect
cost included cost of disposable and nondisposable
diapers, excess wear on bedclothes and sheets, washing
and drying and the caregiver’s time. The cost of these
assumed 5 wet nights per week. Effectiveness was deter-
mined when there was a signiﬁcant increase in dry patient
nights.
RESULTS: The cost effectiveness ratio (total cost effec-
tiveness) for IBM is $14,607 versus $17,608 and $19,644
respectively for IBM, oral and inhaled DDAVP for a com-
plete treatment cycle. One-way sensitivity analysis did not
substantially alter the results.
CONCLUSION: The model identiﬁes Intensive Be-
havioral Management as cost effective treatment of Pri-
mary Nocturnal Enuresis.
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OBJECTIVE: An economic model was developed to 
estimate the comparative cost-effectiveness of tolterodine
extended-release and immediate-release for overactive
bladder (OAB) in Norway.
METHODS: The study population included patients
seeking OAB treatment divided into successfully treated
patients (STP), deﬁned by clinical efﬁcacy and adjusted
by annual persistency, and patients failing treatment
(PFT). Direct costs included drugs, incontinence pads,
physician visits, lab tests/diagnostics and associated
comorbidities. Indirect costs included lost productivity,
comprised of missed/reduced work, caregiver time and
reduced activities of daily living. Resource utilization,
productivity losses and cost data were integrated from a
comprehensive literature review, the National Insurance
Administration, national statistics, a telephone survey,
and expert medical panels. A societal perspective was
taken to model a one-year time horizon.
RESULTS: The prevalence of OAB in Norway is esti-
mated to be 17% of people over age 40 in 2001 (approx-
imately 337,000 people or 7.5% of the Norwegian
population), with only 20% of those patients seeking
treatment. STP use fewer pads per day, visit physicians
less frequently, have fewer lab tests/diagnostics, experi-
ence fewer comorbidities, and have smaller productivity
losses than PFT. Cost drivers are productivity losses (STP:
NOK23251 (€2914) vs. PFT: NOK42851 (€5370)) and
pad usage (STP: NOK300 (€38) vs. PFT: NOK1748
(€219)) (average annual costs per patient). Tolterodine
extended-release (TER) had an 18% greater efﬁcacy than
tolterodine immediate-release (TIR) and persistence on
therapy was higher for TER. Therefore, effectiveness was
higher for TER versus TIR. Cost per STP was NOK69586
(€8720) for TER and NOK95530 (€11972) for TIR. 
TER is the dominant treatment strategy in the analysis,
with an incremental cost-effectiveness of—NOK16416 
(-€2057).
CONCLUSION: Tolterodine extended-release is a more
cost-effective treatment than tolterodine immediate-
release in treating OAB as measured by cost per success-
fully treated patient in Norway.
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OBJECTIVES: Urinary antispasmodics (UA) are the most
common group of pharmaceuticals in the treatment of
urinary and overactive bladder disorders (OAB). This
study compares a population of employees diagnosed
with OAB and actively seeking a pharmacological treat-
ment regimen to those who are not seeking such treat-
ment. A large, multi-employer database was used to 
